NCT07494565

Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL

A Multicenter, Prospective, Randomized, Open-Label, Phase II Study of Celecoxib Combined With R-CHOP Versus R-CHOP in Patients With Newly Diagnosed Advanced CD5-Positive Diffuse Large B-Cell Lymphoma (CD5+ DLBCL)

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of celecoxib combined with R-CHOP versus R-CHOP in the treatment of newly diagnosed advanced CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL).The primary endpoint is Complete Response Rate (CRR)

Conditions

• Diffuse Large B-Cell Lymphoma (DLBCL)
• CD5 Positive

Interventions

Type	Name	Description
DRUG	Celecoxib Combined with R-CHOP	Drug Dose Administration Time Rituximab (Innovent) 375 mg/m², iv Day 1 Cyclophosphamide 750 mg/m², iv Day 1 Doxorubicin 50 mg/m², iv Day 1 Vincristine 1.4 mg/m² (max. 2 mg), iv Day 1 Prednisone 60 mg/m², po Days 1-5 Celecoxib 200 mg, po, BID Days -3 to +2
DRUG	R-CHOP	Drug Dose Administration Time Rituximab (Innovent) 375 mg/m², iv Day 1 Cyclophosphamide 750 mg/m², iv Day 1 Doxorubicin 50 mg/m², iv Day 1 Vincristine 1.4 mg/m² (max. 2 mg), iv Day 1 Prednisone 60 mg/m², po Days 1-5

Timeline

• Start date: 2026-03-05
• Primary completion: 2026-12-31
• Completion: 2028-12-31
• First posted: 2026-03-27
• Last updated: 2026-03-27

Locations

1 site across 1 country: China